Table 1 General characteristics of 153 study patient.
Characteristic | n (%) |
|---|---|
Sex | |
Female | 65 (42,5) |
Male | 88 (57,5) |
Age | |
< 65 ≥ 65 | 101 (66) 51 (33,3) |
ECOG PS | |
0 | 82 (53,6) |
1 | 60 (39,2) |
2 | 10 (6,5) |
Smoking history | |
Never smoked | 75 (49) |
Ex-smoker | 39 (25.5) |
Current smoker | 16 (10.5) |
Pathologic subtype | |
Intestinal | 90 (58,8) |
Diffuse | 63 (41,2) |
Primary tumor location | |
Gastric | 120 (78,4) |
GEJ | 33 (21,6) |
Curative surgery for primary tumor | |
Present | 38 (24,8) |
Absent | 115 (75,2) |
Initial stage | |
Locally advanced | 29 (19) |
Metastatic | 124 (81) |
Site of metastasis | |
Liver | 68 (44,4) |
Periton | 68 (44,4) |
Distant lymph nodes | 49 (32) |
Lung | 24 (15,7) |
Bone | 20 (13,1) |
Brain | 2 (1,3) |
Chemoterapy regimen | |
FOLFOX | 138 (90,2) |
XELOX | 9 (5,9) |
FOLFIRI | 4 (2,6) |
DCF | 2 (1,3) |
PD-L1 CPS (%) | |
5–9 | 42 (27,5) |
10–19 | 47 (30,7) |
20–49 | 38 (24,8) |
≥ 50 | 26 (17) |
MSI Status | |
dMMR | 6 (3.9) |
pMMR | 64 (41.8) |
Unknown | 83 (54.3) |
